Leuprorelin depot injection: patient considerations in the management of prostatic cancer

References

• AkazaHTrends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspectiveCancer Sci200697243716630114
   PubMed Web of Science ®Google Scholar
• AkazaHEfficacy of primary hormone therapy for localized or locally advanced prostate cancer:results of a 10-year follow-upBJU Int200698573916925756
   PubMed Web of Science ®Google Scholar
• AndroutsosGJohn Hunter (1728–1793):fondateur de la chirurgie scientifique et précurseur de l’urologieProg Urol199881087969894276
   PubMedGoogle Scholar
• BarqawiAAkdumanBAbouelfadelZThe use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancerBJU Int200392695814616448
   PubMed Web of Science ®Google Scholar
• BarqawiABMoulJWZiadaACombination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapyUrology200362872614624911
   PubMed Web of Science ®Google Scholar
• BasariaSMullerDCCarducciMAHyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapyCancer2006106581816388523
   PubMed Web of Science ®Google Scholar
• BayoumiAMBrownADGarberAMCost-effectiveness of androgen suppression therapies in advanced prostate cancerJ Natl Cancer Inst2000921731911058616
   PubMed Web of Science ®Google Scholar
• BeerTMExperimental use of GnRH antagonists as second-line hormonal therapyRev Urol20046S33816985935
   PubMedGoogle Scholar
• BergesRBelloUEffect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancerCurr Med Res Opin2006226495516684425
   PubMed Web of Science ®Google Scholar
• Boccon-GibodLFournierGBottetPFlutamide versus orchidectomy in the treatment of metastatic prostate carcinomaEur Urol19973239159412794
   PubMed Web of Science ®Google Scholar
• Braga-BasariaMDobsASMullerDCThe metabolic syndrome in men with prostate cancer undergoing long term androgen deprivation therapyJ Clin Oncol20062439798316921050
   PubMed Web of Science ®Google Scholar
• BrawerMKThe evolution of hormonal therapy for prostatic carcinomaRev Urol20013S11116986002
   PubMedGoogle Scholar
• BurchardtMBurchardtTChenMWVascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castrationProstate2000431849410797493
   PubMed Web of Science ®Google Scholar
• ButtyanRGhafarMAShabsighAThe effects of androgen deprivation on the prostate gland:cell death mediated by vascular regressionCurr Opin Urology20001041520
   PubMedGoogle Scholar
• ByarDPCorleDKHormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studiesNCI Monogr19881651703050535
   PubMedGoogle Scholar
• CassilethBRPatients’ choice of treatment in stage D prostate cancerUrology19893357592523612
   PubMed Web of Science ®Google Scholar
• CavarrettaITRCuligZKlockerHNovel experimental therapeutic approaches for prostate cancerEUA Update Series2005322739
   Google Scholar
• ChodakGWA critical review of maximal androgen blockade for advanced prostate cancerRev Urol200461823
   Google Scholar
• ChodakGWMaximum androgen blockade: a clinical updateRev Urol200571317
   PubMedGoogle Scholar
• ChrispPSorkinEMLeuprorelin:a review of its pharmacology and therapeutic use in prostatic disordersDrugs Aging199114875091794035
   PubMedGoogle Scholar
• ChuFMJaysonMDineenMKA clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol2002168119920312187267
   PubMed Web of Science ®Google Scholar
• ConnPMRogerSCSeaySGBiphasic regulation of gonadotropin-releasing hormone receptor by receptor micro-aggregation and intracellular Ca2 levelsMed Pharmacol1984255155
   Google Scholar
• CoppageWSJrCoonerAETestosterone in human plasmaN Engl J Med196527390275832873
   PubMed Web of Science ®Google Scholar
• CrawfordEDEisenbergerMAMcLeonDGA controlled trial of leuprolide with and without flutamide in prostatic carcinomaN Engl J Med1989321419242503724
   PubMed Web of Science ®Google Scholar
• CrawfordEDSartorOChuFA 12-month clinical study of LA-2585 (45.0 mg):a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol2006175533616406989
   PubMed Web of Science ®Google Scholar
• DebruyneFMJGonadotropin-releasing hormone antagonist in the management of prostate cancerRev Urol20046S253216985933
   PubMedGoogle Scholar
• DenisLJKeuppensFSmithPHMaximal androgen blockade: final analysis of EORTC phase III trial 30853Eur Urol199833144519519355
   PubMed Web of Science ®Google Scholar
• DenmeadeSRIsaacsJTDevelopment of prostate cancer treatment: the good newsProstate2004582112414743459
   PubMed Web of Science ®Google Scholar
• DenmeadeSRLinXSIsaacsJTRole of programmed (apoptotic) cell death during the progression and therapy for prostate cancerProstate199628251658602401
   PubMed Web of Science ®Google Scholar
• FergussonJDImplantation of radioactive material into the pituitary for the control of prostatic cancerBr J Urol1957292152213471943
   PubMedGoogle Scholar
• FowlerJEFlanaganMGleasonDMEvaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancerUrology2000a556394210792069
   PubMed Web of Science ®Google Scholar
• FowlerJEGottelsmanJEReidCFSafety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancerJ Urol2000b164730410953135
   PubMed Web of Science ®Google Scholar
• Franck-LissbrantIHaggstromSDamberJETestosterone stimulates angiogenesis and vascular re-growth in the ventral prostate in castrated adult ratsEndocrinology199813945169449610
   PubMed Web of Science ®Google Scholar
• FreedlandSJPartinAWEarly hormonal therapy for prostate cancer: the good, the bad and the uglyRev Urol20057187816985828
   PubMedGoogle Scholar
• FujinoMFukudaTShinagawaSSynthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10Biochem Biophys Res Commun197460406134608231
   PubMed Web of Science ®Google Scholar
• GleaveMEGoldenbergSLChinJLRandomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effectsJ Urol2001166500611458055
   PubMed Web of Science ®Google Scholar
• GreenspanSICoatesPSereikaSMBone loss after initiation of androgen deprivation therapy in patients with prostate cancerJ Clin Endoc Metab20059064107
   PubMed Web of Science ®Google Scholar
• HallEJRadiobiology for radiobiologist20005PhiladelphiaLippincot Wilkins
   Google Scholar
• HomeEPractical observations on the treatment of the diseases of the prostate gland1811LondonNicol
   Google Scholar
• HugginsCClarkPJQuantitative studies of prostatic secretion. II. The effect of castration and of estrogenic injections on the normal and on the hyperplasic prostate glands of dogsJ Exp Med19407274761
   PubMedGoogle Scholar
• HugginsCHodgesCUStudies on prostate cancer:the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostateCancer Res19411293
   Google Scholar
• HugginsCScottWWBilateral adrenalectomy in prostatic cancer:clinical features and urinary excretion of 17-ketosteroids and estrogenAnn Surg194512210314117858696
   PubMed Web of Science ®Google Scholar
• HugginsCStevensREJrHodgesCVStudies in prostatic cancerArch Surg19414320923
   Google Scholar
• IsaacsJTAntagonistic effect of androgen on prostatic cell deathProstate19845545576483690
   PubMed Web of Science ®Google Scholar
• IsaacsJTRole of androgens in prostate cancerVitam Horm1994494335027810075
   PubMed Web of Science ®Google Scholar
• IversenPOrchidectomy and oestrogen therapy revisitedEur Urol1998347119854189
   PubMed Web of Science ®Google Scholar
• IversenPMelezinekISchmidtANonsteroidal antiandrogens:a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and functionBJU Int200187475611121992
   PubMed Web of Science ®Google Scholar
• JacobiGHIntramuscular cyproterone acetate for advanced prostatic carcinoma:results of the first multicentre trialIn Androgens and anti-androgens1983NetherlandsSchering16170
   Google Scholar
• JanoffDMPetersonCMongoue-TchokoteSValue of androgen ablation in conjunction with radiation for locally advanced Pca: clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancerBJU Int200596503716104900
   PubMed Web of Science ®Google Scholar
• KeyesELFergusonRSKeyesELFergusonRSTreatment of malignant tumors of the prostateUrology19366New YorkAppleton-Century4256
   Google Scholar
• KhanMSO’BrienAAn evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostateUrol Int19986033409519419
   PubMed Web of Science ®Google Scholar
• KirkDImmediate vs. delayed hormone treatment for prostate cancer: how safe is androgen deprivation?Brit J Uro Int200086220 Abstract MP6.1.07
   Google Scholar
• KirkDComment on: Can androgen deprivation be considered a primary treatment for prostate cancer?Nat Clin Pract Urol20063127
   Google Scholar
• KoupparisARamsdenAPersadRCognitive effects of hormonal treatment for prostate cancerBJU Int2004939151615142135
   PubMed Web of Science ®Google Scholar
• KumarRJBarqawiAlCrawfordEDAdverse events associated with hormonal therapy for prostate cancerRev Urol200573743
   PubMedGoogle Scholar
• LabrieFCandasBGomezJLCan combined androgen blockade provide long-term control or possible cure of localized prostate cancer?Urology200260115912100935
   PubMed Web of Science ®Google Scholar
• LeibovitzRLTuckerSJTreatment of localized prostate cancer with intermittent triple androgen blockade:preliminary results in 110 consecutive patientsOncologist20016177811306729
   PubMed Web of Science ®Google Scholar
• LoweFCBambergerMHIndications for use of ketoconazole in management of metastatic prostate cancerUrology1990365412247927
   PubMed Web of Science ®Google Scholar
• [LPG] The Leuprolide Study GroupLeuprolide versus diethylstilbestrol for metastatic prostate cancerN Engl J Med1984311128166436700
   PubMed Web of Science ®Google Scholar
• [LSG] The Leuprolide Study GroupLeuprolide versus diethylstilbesterol for metastatic prostate cancerN Engl J Med1984311128166436700
   PubMed Web of Science ®Google Scholar
• LyonsJAKupelianPAMohanDSImportance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostateUrology200055859010654900
   PubMed Web of Science ®Google Scholar
• MaloneSPerryGEapenLMature results of the Ottawa Phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome Prostate-specific Antigen-only RecurrenceInt J Radiat Oncol Biol Phys20076869970617379438
   PubMed Web of Science ®Google Scholar
• MaloneSPerryGSegalRLong-term side-effects of intermittent androgen suppression therapy in prostate cancer:results of a phase II studyBJU Int2005965142016104902
   PubMed Web of Science ®Google Scholar
• MarianiAJGloverMAritaSMedical versus surgical androgen suppression therapy for prostate cancer:a 10-year longitudinal cost studyJ Urol2001165104711125375
   PubMed Web of Science ®Google Scholar
• MarkLSLuteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer:timing, alternatives, and the 1-year implantUrology2003623642
   Web of Science ®Google Scholar
• MassoudWPaparelPLopezJGDiscovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancerInt J Urol200613303416643633
   PubMed Web of Science ®Google Scholar
• MazzeiTMiniERizzoMHuman pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patientsJ Int Med Res19901842562108885
   PubMed Web of Science ®Google Scholar
• McLeodDZinnerNTomeraKAberalix Study Group.A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerUrology2001587566111711355
   PubMed Web of Science ®Google Scholar
• McLeodDGTolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancerOncologist19972182710388026
   PubMedGoogle Scholar
• McLeodDGHormonal therapy:historical perspective to future directionUrology2003613712667881
   PubMed Web of Science ®Google Scholar
• MercaderMSenguptaSBodnerBKEarly effects of pharmacological androgen deprivation in human prostate cancerBJU Int200799606717227493
   PubMed Web of Science ®Google Scholar
• MessingEMMonolaJSarodsyMImmediate hormonal therapy compared with observation following radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancerN Engl J Med19993411781810588962
   PubMed Web of Science ®Google Scholar
• MigliariRMuscasGMurruMAntiandrogens:a summary review of pharmacodynamic properties and tolerability in prostate cancer therapyArch Ital Urol Androl19997129330210673793
   PubMedGoogle Scholar
• MillerKSteinerULingnauRandomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancerASCO20075015 Abstract
   Google Scholar
• MonahanMWAmossMSAndersonHASynthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist propertiesBiochemistry1973124616204589943
   PubMed Web of Science ®Google Scholar
• MontgomeryBSBorwellJPHigginsDMDoes needle size matters? Patient experience with luteinizing hormone releasing hormone analogueProstate Cancer Prostatic Dis2005866815700050
   PubMed Web of Science ®Google Scholar
• MoroteJEsquenaSAbascalJMFailure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancerUrol Int200677135816888418
   PubMed Web of Science ®Google Scholar
• MoulJWWuHSunLEarly versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomyJ Urol20041711141714767288
   PubMed Web of Science ®Google Scholar
• MoulJWThe evolving definition of advanced prostate cancerRev Urol20046S101616985915
   PubMedGoogle Scholar
• [MRC] The Medical Research Council Prostate Cancer Working Party Investigators GroupImmediate versus deferred treatment for advanced prostatic cancer:initial results of the Medical Research Council TrialBr J Urol199779235469052476
   PubMedGoogle Scholar
• MurphyWTSchwippertHPituitary irradiation in prostatic cancerRadiology1951563768014834413
   PubMed Web of Science ®Google Scholar
• NewlingDWWAnti-androgens in the treatment of prostate cancerBr J Urol199677776848705208
   PubMedGoogle Scholar
• OefeieinMGComumRFailure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy:the case for monitoring serum testosterone and a treatment decision algorithmJ Urol2000164726910953134
   PubMed Web of Science ®Google Scholar
• OefeleinMGFengAScolieriMJReassessment of the definition of castrate levels of testosterone:implications for clinical decision makingUrology2000561021411113751
   PubMed Web of Science ®Google Scholar
• OrnsteinDKBeiserJAAndrioleGLAnaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancerBJU Int19998343610233450
   PubMed Web of Science ®Google Scholar
• PainterMRReimbursement issues with hormonal therapies for prostate cancerRev Urol20057S44716985884
   PubMedGoogle Scholar
• ParmarHLightmanSLAllenLRandomised controlled study of orchidectomy vs. long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinomaLancet19852120152866289
   PubMed Web of Science ®Google Scholar
• Pavone-MacalusoMFlutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre, randomised studySIU 23rd Congress1994A354
   Google Scholar
• PeehlDMBasic science of hormonal therapy for prostate cancerRev Urol200131522
   Google Scholar
• Perez-MarenoRChuFMGleasonDA six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerCli Ther200224190214
   PubMed Web of Science ®Google Scholar
• PeritiPMazzeiTMiniEClinical pharmacokinetics of depot leuprorelinClin Pharmacokinet20024148550412083977
   PubMed Web of Science ®Google Scholar
• PetrylakDPThe Current role of chemotherapy in metastatic hormone-refractory prostate cancerUrology2005653815885271
   PubMed Web of Science ®Google Scholar
• PetrylakDPNew paradigms for advanced prostate cancerRev Urol20079312
   PubMedGoogle Scholar
• PilepichMVAndrogen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31Int J Radiat Oncol Biol Phys20056112859015817329
   PubMed Web of Science ®Google Scholar
• PontALong term experience with high dose ketoconazole therapy in patients with D2 prostatic carcinomaJ Urol19871379022437334
   PubMed Web of Science ®Google Scholar
• PoundRPartinAWEisenbergerMANatural history of progression after PSA elevation following radical prostatectomyJAMA19992811591710235151
   PubMed Web of Science ®Google Scholar
• ReddingTWSchallyAVInhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormoneProc Natl Acad Sci USA1983801459626219395
   PubMed Web of Science ®Google Scholar
• RyanCJElkinEPSmallEJReduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSUREUrol Oncol20062439640216962488
   PubMed Web of Science ®Google Scholar
• SandfordNLSearleJWKerrJFSuccessive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulationPathology198416406106522105
   PubMed Web of Science ®Google Scholar
• SandowJvon RechenbergWEngelbartKPharmacological studies on androgen suppression in therapy of prostate carcinomaAm J Clin Oncol198811S6103291602
   PubMedGoogle Scholar
• SatterthwaiteRWHillJHPackardEEExperimental and clinical evidence on the role of the 17 keto-steroids in prostatic carcinomaJ Urol194146114954
   Google Scholar
• SchallyAVArimuraABabaYIsolation and properties of the FSH and LH-releasing hormoneBiochem Biophys Res Commun19714339394930860
   PubMed Web of Science ®Google Scholar
• SchlegelPNHistrelin Study Group. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancerJ Urol20061751353816515997
   PubMed Web of Science ®Google Scholar
• ScholzMJennrichRStrumSLong-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisoneJ Urol2005173194795215879788
   PubMed Web of Science ®Google Scholar
• SchröderFHWalshPCRetikABVaughnEDJrHormonal therapy of prostate cancerCampbell’s urology20028PhiladelphiaWB Saunders3182208
   Google Scholar
• SeeWAAdjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancerCurr Treat Options Oncol200343516212941195
   PubMedGoogle Scholar
• SeidenfeldJSamsonDJHasselbladVSingle-therapy androgen suppression in men with advanced prostate cancer:a systematic review and meta-analysisAnn Intern Med20001325667710744594
   PubMed Web of Science ®Google Scholar
• ShabisghATanji N’ D’AgatiVEarly effects of castration on the vascular system of the rat ventral prostate glandEndocrinology19991401920192610098532
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLRisk of fracture after androgen deprivation for prostate cancerN Engl J Med20053521546415647578
   PubMed Web of Science ®Google Scholar
• SharifiRKnollLDSmithJLeuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancerUrology19985127169495710
   PubMed Web of Science ®Google Scholar
• SharifiRRatanwongCJungATherapeutic effects of leuprorelin microspheres in prostate cancerAdv Drug Deliv Rev1997281213610837568
   PubMed Web of Science ®Google Scholar
• SilverbergGDBrittRHTrans-sphenoidal hypophysectomy in the treatment of metastatic breast and prostate carcinomaWest J Med19791301915425500
   PubMedGoogle Scholar
• SmallEJRyanCJThe case for secondary hormonal therapies in the chemotherapy ageJ Urol2006176S667117084172
   PubMed Web of Science ®Google Scholar
• SmithMRObesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancerClin Cancer Res200713241517200361
   PubMed Web of Science ®Google Scholar
• SoganiPCRayBWhitmoreWFAdvanced prostatic carcinomaUrology1975616461145932
   PubMedGoogle Scholar
• StuderUWhelanPAlbrechtWImmediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organization for Research and Treatment of Cancer Trial 30 891J Clin Oncol20062418687616622261
   PubMed Web of Science ®Google Scholar
• TabataK8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancerNippon Hinyokika Gakkai Zasshi200697712816898594
   PubMedGoogle Scholar
• TanejaSSA multidisciplinary approach to the management of hormone-refractory prostate cancerRev Urol200358591
   Google Scholar
• ThompsonIMFlare associated with LHRH-agonist therapyRev Urol20013101416985686
   PubMedGoogle Scholar
• TogushiHFormulation study of leuprorelin acetate to improve clinical performanceClin Ther199214121301606592
   PubMed Web of Science ®Google Scholar
• TolisGAckmanDTellosSTumour growth inhibition in patients with prostaic carcinoma treated with luteinising hormone releasing hormone agonistsProc Nat Acad Sci USA1982791658626461861
   PubMed Web of Science ®Google Scholar
• TrachtenbergJGittlemanMSteidleCA phase 3, multicenter, open-label randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancerJ Urol20021671670411912385
   PubMed Web of Science ®Google Scholar
• TrachtenbergJPointAKetoconazole: a novel and rapid treatment for advanced prostate cancerJ Urol19831301526306286
   PubMed Web of Science ®Google Scholar
• TrachtenbergJThe treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogueJ Urol19831291149526406688
   PubMed Web of Science ®Google Scholar
• UchidaTIllingROCathcartPJThe effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapyBJU Int200698770216879448
   PubMed Web of Science ®Google Scholar
• UsamiMBicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patientsProstate Cancer Prostatic Dis20071019420117199134
   PubMed Web of Science ®Google Scholar
• Van LoenenACHuirneJASchatsRGnRH agonists, antagonists, and assisted conceptionSemin Reprod Med20022034912536358
   PubMed Web of Science ®Google Scholar
• WardJFMoulJWBiochemical recurrence after definitive prostate cancer therapy. Part I:defining and localizing biochemical recurrence of prostate cancerCurr Opin Urol200515181615815195
   PubMed Web of Science ®Google Scholar
• WechselHWZerbibMPaganoFRandomized opabelledled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancerEur Urol199630714 discussion 19–218977984
   PubMed Web of Science ®Google Scholar
• WhitakerISFazelMZJoshiHBLeuprorelin acetate granulomas:recurrent subcutaneous nodules mimicking metastatic deposits at injections sitesBJU Int20029035012133078
   PubMed Web of Science ®Google Scholar
• WhiteJWThe results of double castration in hyper-trophy of the prostateAnn Surg18952213
   PubMedGoogle Scholar
• WhiteJWThe present position of surgery of the hypertrophied prostateAnn Surg19044078892
   Google Scholar
• YamanakaHMakinoTKumasakaFClinical efficacy of (DLeu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancerHinyokika Kiyo19843054566435416
   PubMedGoogle Scholar
• YoungHHIIKentJRPlasma testosterone levels in patients with prostatic carcinoma before and after treatmentJ Urol196899788924871357
   PubMed Web of Science ®Google Scholar
• ZietmanALThe case for neoadjuvant androgen suppression before radiation therapyMol Urol200042038 discussion 21511062375
   PubMedGoogle Scholar